Devices Escape Comparative Effectiveness Study Focus With Limelight On Rx
This article was originally published in The Gray Sheet
Executive Summary
The device industry has once again received a reprieve from comparative effectiveness trial provisions as policymakers remain centered on controlling pharmaceutical costs
You may also be interested in...
Medical Journals To Require Registration Of Devices On ClinicalTrials.Gov
Medical device firms as well as pharmaceutical companies will be required to register their clinical trials in a public registry as a prerequisite of journal publication, according to New England Journal of Medicine Executive Editor Gregory Curfman, MD
Device Industry Mindful Of AHRQ Cost-Effectiveness Agenda, Due June 8
The device industry will discuss with AHRQ the need to consider long-term costs of new technology underutilization as the agency develops its cost-effectiveness research agenda
Clinical Trial Priority List Advocated By CMS Coverage Chief, AHRQ Director
The Institute of Medicine should develop a list of "knowledge gaps" to help establish priorities for public and private funders of clinical trials, according to an editorial by CMS and AHRQ staffers in the Sept. 24 Journal of the American Medical Association.